Tucker Asset Management LLC Sells 1,342 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Tucker Asset Management LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 19.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,598 shares of the biopharmaceutical company’s stock after selling 1,342 shares during the quarter. Tucker Asset Management LLC’s holdings in Gilead Sciences were worth $517,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of GILD. State Street Corp raised its position in Gilead Sciences by 1.4% in the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock worth $5,044,795,000 after purchasing an additional 841,776 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Gilead Sciences by 50.9% in the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after buying an additional 11,665,593 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Gilead Sciences by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock worth $2,302,119,000 after buying an additional 574,421 shares during the period. Norges Bank bought a new position in shares of Gilead Sciences during the fourth quarter valued at $1,789,254,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Gilead Sciences by 3.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 8,002,779 shares of the biopharmaceutical company’s stock valued at $739,217,000 after purchasing an additional 249,804 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $111.79 on Friday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The firm has a market cap of $139.22 billion, a price-to-earnings ratio of 302.14, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The stock’s 50-day moving average is $105.48 and its 200-day moving average is $94.81.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were issued a $0.79 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.83%. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on GILD shares. Bank of America lifted their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Oppenheimer increased their target price on Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a report on Tuesday, March 4th. Finally, Piper Sandler lifted their price target on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $105.12.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 17,929 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the sale, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $19,977,938.37. This trade represents a 9.59 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last quarter, insiders have sold 302,785 shares of company stock worth $30,503,250. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.